featured
Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2021 Oct 26;[EPub Ahead of Print], S Banerjee, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, A Lisyanskaya, A Floquet, A Leary, GS Sonke, C Gourley, A Oza, A González-Martín, C Aghajanian, WH Bradley, E Holmes, ES Lowe, P DiSilvestroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.